mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Maxwell Biotech GroupMaxwell Biotech Group

  • Myrcludex B
    Therapeutic focus: Chronic viralhepatitis B (HBV); chronic hepatitis D (HDV).

  • BNV-222, aldose reductase inhibitor (ARI)
    Therapeutic focus: diabetic peripheral neuropathy

  • The first drug in the company's portfolio is SQ109
    for the treatment of multidrug-resistant TB (MDR-TB).

  • Leading drug OС000459
    Therapeutic focus: asthma and other respiratory diseases

  • MBC-11 is chemically synthesized unique conjugate of two molecules
    (etidronate and cytarabine) designed for treatment of multiple myeloma,
    osteosarcoma, as well as metastatic bone lesions. The mechanism of action
    of this drug is based on the ability of bisphopsphonate part of the molecule
    to deliver the conjugate to the site of bone destruction (targeted delivery).

Maxwell Biotech Group

Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with representatives in Boston (USA).

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. Four products are in the registration phase of clinical studies.

© Maxwell Biotech Group Ltd.

TOP